Degussa enters biopharmaceutical market
The fine chemicals business unit of Duesseldorf-based Degussa is entering the biopharmaceuticals market by combining the oligonucleotide business line of Degussa subsidiary Proligo, based in Boulder, Colorado, with its GMP custom manufacturing operation at Raylo Chemicals in Edmonton in Canada.
The fine chemicals business unit of Duesseldorf-based Degussa is entering the biopharmaceuticals market by combining the oligonucleotide business line of Degussa subsidiary Proligo, based in Boulder, Colorado, with its GMP custom manufacturing operation at Raylo Chemicals in Edmonton in Canada.
The transfer, which was effective from 1 November, allows Proligo to focus on providing consumables for genetic information processing through the supply of nucleic acid reagents and small-scale oligonucleotides for research use.
The fine chemicals business unit will develop and produce oligonucleotides in a new cGMP plant at the Edmonton site, where Raylo manufactures APIs. The oligonucleotide production facility at Boulder will continue to focus on product development and production of quanitites up to kilograms for early clinical phases, but will now be managed as part of Raylo's business.